Trial Profile
A 12 Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CEP 10953 (150 mg) as Treatment for Adults With Excessive Sleepiness Associated With Chronic Shift Work Sleep Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jul 2011
Price :
$35
*
At a glance
- Drugs Armodafinil (Primary)
- Indications Circadian rhythm sleep disorders
- Focus Therapeutic Use
- Sponsors Cephalon
- 05 Nov 2010 New trial record.